[Combination therapies using cyclooxygenase-2 inhibitors and angiotensin-converting enzyme inhibitors in colon carcinogenesis].
Yasumaru
Masakazu
M
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine.
Tsujii
Masahiko
M
Tsuji
Shingo
S
D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000502:physiology; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000037:antagonists & inhibitors / Q000502:physiology; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D016861:Cyclooxygenase Inhibitors; D000804:Angiotensin II; D007335:Insulin-Like Growth Factor II; D017526:Receptor, IGF Type 1; D015232:Dinoprostone